OBJECTIVES: To assess patients’ knowledge of chronic myeloid leukemia (CML) treatment response categorizations and to evaluate health-related quality-of-life (HRQOL) outcomes and treatment satisfaction among CML patients achieving different levels of responses.  METHODS: CML patients were invited to complete an on-line survey that assessed their knowledge of different CML treatment-response categorizations. Data on HRQOL outcomes and treatment satisfaction were also collected. Chi-square and Fisher’s test were used for statistical comparisons. RESULTS: 123 patients obtained through the ACOR database completed the survey. The mean age of respondents was 63 years, 48.8% were male, and 95.9% had some level of college experience. Over 90% were familiar with the different levels of CML treatment responses, with 96.8% self-reporting a current hematologic response, 70.7% a current cytogenetic response, and 68.3% a molecular response. However, 71.5% felt CML patients need more information on the types of responses, with the desire for information to come from their physicians (66.7%) rather than from other staff (28.5%) or pamphlets (23.6%). Achieving a molecular response (as opposed to hematologic/cytogenetic responses) generated the greatest satisfaction with their physician (78.6%), medication (86.6%), outlook on life (85.7%), and day-to-day functioning (85.7%). The percentage of patients rating their own health as excellent/very good was 43.1% among those with a molecular response and 41.7% with a cytogenetic response. However, 21.9% of all subjects rated their health as fair/poor. CONCLUSIONS: Achievement of a molecular response was associated with a higher satisfaction with a patient’s physician, medication, and outlook on life, as well as an overall improvement in self-reported health ratings. Even in this highly educated ACOR population, a need for physician-directed information about various response criteria and counseling about the value of obtaining a molecular response is desired.